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Current diagnostic tests lack sensitivity for the identification of the bacterial etiology of pneumonia. Attempts
during the past 2 decades to improve sensitivity of detection of bacterial constituents in blood by use of
antibody-antigen complexes and polymerase chain reaction have been disappointing. Recent data using pneu-
mococcal conjugate vaccines as probes suggest that increased levels of both C-reactive protein and procalcitonin
may be useful adjuncts to chest radiographs in the selection of patients with presumed bacterial pneumonia
for inclusion in clinical trials. Among pneumococcal diagnostics currently under investigation, quantitative
real-time polymerase chain reaction of respiratory secretions, as well as urinary antigen detection and pneu-
mococcal surface adhesin A serological analysis for adults, are candidates for use in future clinical trials of
antibiotics.
Acute respiratory infections are the leading infectious
cause of death globally among both infants and adults
[1]. Although these deaths are, in large part, attributable
to community-acquired pneumonia (CAP) caused by
Streptococcus pneumoniae [2], our ability to identify
pneumococci as the specific etiological agent of pneu-
monia is very limited.
Although culture of lung puncture aspirate may in-
crease the yield of pneumococci, relative to blood cul-
ture alone, its sensitivity for diagnosing pneumococcal
pneumonia is !20% [2, 3]. Additionally, other invasive
techniques, such as bronchoalveolar lavage and pro-
tected specimen brush sampling, are not practical to
use to define the role of pneumococci in patients with
CAP who are routinely enrolled in clinical trials.
This article reviews advances in the specific diagnosis
of pneumococcal infections in CAP. It starts with an
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overview of the insights gained from trials of conjugate
pneumococcal vaccine on the role of chest radiographs
and acute inflammatory responses in helping to define
pneumococcal CAP and then looks at molecular and
serological advances in the diagnosis of pneumococcal
CAP for both children and adults.
PNEUMOCOCCAL CAP EXTENDS
BEYOND CONSOLIDATION SEEN ON
CHEST RADIOGRAPHS
Evidence of alveolar consolidation seen on chest ra-
diograph is usually used to define the subset of patients
with acute respiratory infections that have progressed
to CAP. Although it is recognized that chest radiographs
may not manifest alveolar consolidation early in the
course of disease, particularly in pediatric studies, it has
been difficult, in the absence of a sensitive diagnostic
assay, to define a role for pneumococci in patients with
pneumonia who do not have classic changes seen on
chest radiographs [4].
Although pneumococcal conjugate vaccine trials in-
volving children have demonstrated a decrease in the
incidence of World Health Organization–defined con-
solidation seen on chest radiograph (chest radiograph
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end point consolidation) among 25%–37% of children receiv-
ing 3 doses of 7- or 9-valent conjugate vaccine [2, 5, 6], the
vaccine has also been used as a probe to investigate the role of
C-reactive protein (CRP) and procalcitonin in defining a pneu-
mococcal etiology. This is done by comparing the incidence of
study end points between vaccine recipients and control in-
dividuals, after blinded determination of CRP and procalci-
tonin levels in archived specimens taken during the randomized
clinical trials [7, 8]. In children with CAP and chest radiograph
end point consolidation, an elevated CRP level identified an
enriched population of patients with pneumonia among whom
the fraction of pneumococcal-vaccine preventable pneumonia
increased (in the intent-to-treat analysis) from 21% to 38% at
a CRP level of 1120 mg/L, and the fraction of pneumococcal-
vaccine preventable pneumonia increased from 21% to 46% as
the procalcitonin level increased to 5 ng/mL [7]. These levels
of acute-phase reactants are too high to be clinically sensitive
but demonstrate increasing specificity of the pneumococcal
fraction of chest radiograph end point pneumonia as levels of
acute-phase reactant increase. Among patients with the com-
bination of high levels of CRP and high levels of procalcitonin,
64% of chest radiograph end point–confirmed CAP cases were
preventable by the conjugate vaccine [7].
With the vaccine probe approach, the use of a CRP value
140 mg/L has been shown to identify a considerable burden
of pneumococcal pneumonia in children with nonspecific
changes seen on chest radiograph [8]. These data suggest that,
at least in studies involving children, an increased CRP level
in situations where any changes are seen on chest radiograph
may be an enriched clinical trial population.
NONQUANTITATIVE PCR ASSAYS FOR S.
PNEUMONIAE
The first generation of PCR assays of blood samples from adults
with CAP had sensitivities less than or equal to those of blood
cultures [9]. Throat swab specimens were probed by PCR of
the ply gene (which encodes pneumolysin) in patients with
pneumonia. Of 417 patients, 229 (55%) had positive results,
but 73 (58%) of 126 control individuals had positive results
[10]. The lack of specificity is now believed to be caused by
the presence of the ply gene in some species of streptococcal
mouth flora. In children, the use of pneumolysin-based non-
quantitative PCR on blood samples is contradictory. Dagan et
al. [11] showed a lack of sensitivity and specificity, whereas a
study by Michelow et al. [12] suggested 100% sensitivity and
95% specificity, compared with blood culture. The data overall
suggest a lack of specificity for the ply gene. A recent report
shows improved specificity with use of a probe for the lytA
gene [13].
QUANTITATIVE REAL-TIME PCR
Recent studies involving adults have investigated quantitative
differences in pneumococcal colonization of the nasopharynx
and sputum by using quantitative real-time PCR. Using the ply
gene as a reporter and a cutoff of 1 genomic equiv-43.7 10
alents per mL of good-quality sputum, sensitivity was 90% and
specificity was 80% [14]. Using the same target at 1105 copies
of ply gene per mL of sputum was more sensitive than was
culture, especially for patients receiving antibiotics [15, 16]. A
more specific target, the Spn9802 gene fragment, at 1104 copies/
mL in nasopharyngeal aspirate specimens is reported to cor-
relate with clinical disease [17]. The Spn9802 gene fragment
compared favorably with quantitative lytA-based real-time PCR
in distinguishing patients with pneumonia from control indi-
viduals [17]. There is some evidence that disease presentation
and severity may correlate with real-time PCR levels of pneu-
mococci in clinical specimens. In patients with pneumococcal
meningitis, the concentration of pneumococcal DNA in blood
and CSF specimens correlated with mortality [18]. Finally, in
the diagnosis of pneumococcal empyema in children, real-time
PCR is more sensitive than is culture [19, 20].
Real-time quantititave PCR of respiratory specimens with
specific primers for genes such as lytA is thus a promising
method for the identification of patients who should be enrolled
in antibiotic trials of CAP. This approach appears to be more
useful than is culture for identifying pneumococcal empyema.
DIFFERENTIAL PATTERNS OF GENE
EXPRESSION
The patterns of gene expression in pneumococci vary between
colonizing and invasive bacteria. In mice, opaque phenotypes
of S. pneumoniae correlate with invasive disease, whereas trans-
parent phenotypes correlate with colonization [21]. The phe-
notype is a function of capsular expression [22] and the ex-
pression of other virulence genes. Virulence genes other than
capsular genes showed greater differential expression than did
capsular genes, in lung and blood specimens of mice but not
in nasal secretions [23]. These observations, however, were
complicated by strain-specific differences in expression that
were also found. Thus, differential gene expression may be a
diagnostic modality of the future—a major hurdle that first
must be overcome is the need to improve the sensitivity of in
situ gene expression [23]. There are also large differences in
host immune protein gene expression between different niches
associated with pneumococcal infection in mice [23]. Thus,
host protein expression may identify specific etiological agents,
such as pneumococci. In mice, pneumococcal infection may
be differentiated from influenza by patterns of host gene ex-
pression [24, 25], and the colonization of human pharyngeal
epithelial cells with pneumococci can similarly be detected by
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changes in the cells’ gene expression [26]. The possibility there-
fore exists that, in the future, patterns of pneumococcal gene
expression detected in the blood may identify invasive strains.
PNEUMOCOCCAL SEROLOGICAL ANALYSIS
Serological analysis is not useful for immediate treatment de-
cisions, but the persistence of an antibody response despite
preceding antibiotic exposure makes serological analysis ap-
pealing for the etiologic diagnosis of pneumococcal disease in
epidemiologic studies. Pneumococcal surface adhesin A (PsaA)
is present in the cell walls of all pneumococcal serotypes and
some oral streptococci [27]. Anti-PsaA ELISA is a possible
method of establishing a diagnosis of pneumococcal pneu-
monia. A serotype 4 outbreak in a nursing home led to hos-
pitalization of 18 patients during a 2-week period. Blood culture
results were positive for 3 patients; 6 other patients showed
evidence of seroconversion to PsaA [28]. In patients with bac-
teremic pneumococcal pneumonia, a 2-fold increase in ELISA
units of anti-PsaA from paired convalescent- and acute-phase
serum samples had 85% sensitivity and 83% specificity [29].
The same assay achieved a sensitivity of 89% and a specificity
of 98% among Kenyan adults with a 1.3-fold cutoff [30]. Un-
fortunately, among children with invasive pneumococcal dis-
ease, sensitivity was poor, and interpretation required higher
cutoff values [31]. Comparison with convalescent-phase serum
samples is necessary because single measurements of PsaA con-
centrations in acute-phase serum specimens lack sensitivity [30,
32]. This is a major limitation of the assay, because clinicians
are unlikely to obtain convalescent-phase serum samples. Pa-
tients enrolled in clinical trials, however, are routinely seen at
the end of treatment and/or at 21–30 days after initiation of
therapy. PsaA seroconversion is currently an underutilized op-
portunity to make pneumococcal diagnoses in clinical trials. A
major limitation of the assay for this purpose is that there is
no US Food and Drug Administration (FDA)–licensed or com-
mercially available assay.
Pneumococcal antigen-antibody immune complexes have
been used in experimental assays to indicate pneumococcal
infection. These assays are not standardized, and their utility
in clinical studies remains to be established [33, 34]. Assays of
pneumococcal antibody using ELISA and including absorption
steps with C-polysaccharide and whole 22F pneumococci have
been standardized by an international effort [35]. The possi-
bility of measuring antibody-specific assays has become prac-
tical with use of simultaneous multiple-assay platforms, such
as Luminex (Luminex Corporation), but, again, their use re-
mains to be clinically established in the trial setting. In con-
clusion, the development of an FDA-licensed serological assay
would be a useful adjunct to the diagnosis of pneumococcal
pneumonia in clinical trials.
PNEUMOCOCCAL URINARY ANTIGEN TESTING
Serotype-specific latex-agglutination urinary assays for pneu-
mococcal serotypes are limited because there are 91 identified
pneumococcal serotypes [36, 37]. An ELISA for urinary pneu-
molysin detection in children has been recently developed.
Compared with the immunochromatographic membrane assay
(ICT) Binax Now S. pneumoniae (Binax), the urinary pneu-
molysin ELISA achieved lower sensitivity for pneumococcal
infection in children with and without nasopharyngeal carriage,
but markedly improved specificity [38]. The low sensitivity of
56.6% in adults likely does not suggest much added benefit in
this age group [38]. The detection of pneumococcal C-poly-
saccharide with the ICT Binax NOW S. pneumoniae assay allows
a bedside diagnosis of pneumococcal disease within 15 min
after receipt of a urine sample [39]. The assay is reported to
have a sensitivity of 74%, specificity of 94%, positive predictive
value of 79%, and negative predictive value of 92% for adults
not infected with HIV who have microbiologically confirmed
pneumococcal disease [40]. The ICT may also be useful for
special populations, such as HIV-infected patients [40] and
critically ill patients [41]. Specificity issues have to be viewed
in light of the limitations of traditional microbiological testing.
In a latent-class analysis, the ICT performed favorably, with
better sensitivity than that of blood and sputum culture and
higher specificity than that of lytA or ply (nonquantitative) PCR
of respiratory samples at comparable sensitivity [42]. The lower
sensitivity of the ICT after antibiotic use that was found in
some studies [37, 43] was not confirmed in others [12, 44].
Discordant results, with negative results of culture for pneu-
mococci and positive results of ICT, were highly associated with
previous use of antibiotics [45]. The measured fraction of pa-
tients with pneumonia of unknown etiology might be reduced
by 23% [40], and the measured fraction of pneumococcal eti-
ology could be increased up to 2-fold by use of this assay. The
limitations of this assay include unacceptably low specificity in
young children, because of correlation with pneumococcal car-
riage [39, 46], although not in adults [47], and possible cross-
reactions with some a-hemolytic oral streptococci (Streptococ-
cus mitis and Streptococcus oralis).
The persistence of positive test results after recovery from
pneumococcal disease is reported for up to 90% of patients 7
days after diagnosis [48] and for 40%–48% after 4–6 weeks
[40, 49]. The persistence of positive assay findings is a particular
problem (occuring for 70% at 1 month) if urine specimens are
concentrated 25-fold with use of ultrafiltration [45]. The added
time, effort, and cost, together with some loss in specificity
from the use of concentrated urine, likely outweigh the sen-
sitivity gained, but the increased sensitivity achieved by urine
concentration might be useful for epidemiological studies.
Severe disease has been associated with higher detection rates
with use of the ICT [50] and higher semiquantitative titers
Diagnosis of S. pneumoniae CAP • CID 2008:47 (Suppl 3) • S205
[51], which might be an indication either of the severity of
pneumococcal disease or simply of a higher pneumococcal bur-
den in severe disease. Bacteremic infections tend to have higher
rates of positivity [50, 52]. Promising results have been reported
for testing of pleural fluid for the diagnosis of empyema [44,
53]. Finally, ICT has been used for management decisions.
Targeted amoxicillin use among Russian military recruits with
nonsevere pneumonia who had positive assay results achieved
similar clinical success rates as did clarithromycin use among
those with negative results [54]. Similarly, in a Swedish study,
a positive result of ICT was associated with higher success rates
of initial b-lactam monotherapy, compared with a negative
result of ICT [55].
CONCLUSIONS
In clinical trials for CAP, S. pneumoniae is the most common
and virulent bacterial pathogen against which empirical treat-
ment is directed. We suggest that the following tests for S.
pneumoniae be included in future clinical trials of both mild
pneumonia in outpatients and severe pneumonia in hospital-
ized patients.
1. Culture of blood and of good-quality sputum
2. S. pneumoniae urinary antigen detection
3. Quantitative assays of CRP and procalcitonin
4. Serological analysis of acute- and convalescent-phase se-
rum samples, pending an FDA-licensed assay for PsaA.
It is possible that, in the near future, specific primers for real-
time PCR will allow the application of this method to respi-
ratory secretions, and perhaps to blood and other bodily fluids,
for quantitative differentiation of pneumococcal pneumonia
from nasopharyngeal carriage.
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